<DOC>
	<DOCNO>NCT02219711</DOCNO>
	<brief_summary>MGCD516 receptor tyrosine kinase ( RTK ) inhibitor show preclinical model inhibit closely related spectrum RTKs include MET , AXL , MER , member VEGFR , PDGFR , DDR2 , TRK Eph family . In study , MGCD516 orally administer patient advance solid tumor malignancy evaluate safety , pharmacokinetic , metabolism , pharmacodynamic clinical activity profile . During Phase 1 segment , dose regimen MGCD516 assess ; Phase 1b segment , clinical activity MGCD516 evaluate select patient population . Patients anticipate enrolled Phase 1b select base upon tumor type , include limited , non small cell lung cancer head neck cancer positive specific activate MET , NTRK2 , NTRK3 , DDR2 mutation , MET KIT/PDGFRA/KDR gene amplification , select gene rearrangement involve MET , RET , AXL , NTRK1 , NTRK3 gene locus , loss function mutation CBL gene . In addition patient clear cell renal cell carcinoma refractory angiogenesis inhibitor metastatic prostate cancer bone metastasis enrol .</brief_summary>
	<brief_title>Phase 1/1b Study MGCD516 Patients With Advanced Cancer</brief_title>
	<detailed_description>During Phase 1 segment , dose regimen MGCD516 assess . During Phase 1b segment , clinical activity MGCD516 evaluate select patient population . Patients anticipate enrolled Phase 1b select base upon follow cancer diagnosis : Non-small cell lung cancer genetic alteration MET , AXL , RET , TRK , DDR2 , KDR , PDGFRA , KIT CBL . Head neck squamous cell carcinoma genetic alteration MET . Clear cell renal cell carcinoma refractory angiogenesis inhibitor . Metastatic prostate cancer bone metastasis . Other cancer diagnosis select genetic alteration MGCD516 target RTKs .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Metastatic unresectable solid tumor malignancy Standard treatment available Adequate bone marrow organ function History significant cardiovascular illness Prolonged correct QT ( QTc ) interval Left ventricular ejection fraction &lt; 40 % Symptomatic uncontrolled brain metastasis Other active cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MGCD516</keyword>
	<keyword>MET</keyword>
	<keyword>AXL</keyword>
	<keyword>RET</keyword>
	<keyword>TRK</keyword>
	<keyword>NTRK</keyword>
	<keyword>DDR2</keyword>
	<keyword>KDR</keyword>
	<keyword>VEGFR</keyword>
	<keyword>PDGFRA</keyword>
	<keyword>KIT</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>CBL</keyword>
</DOC>